Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 Dec;76(12):1702–1706. doi: 10.1136/jnnp.2003.033225

Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: clinical and immunological data

M Tschernatsch 1, E Stolz 1, M Strittmatter 1, M Kaps 1, F Blaes 1
PMCID: PMC1739428  PMID: 16291897

Abstract

Objective: Paraneoplastic neuropathy is a clinical and immunological heterogeneous disorder and attempts have been made to classify subgroups of this disease. Only 30–50% of the clinical defined cases have antineuronal antibodies.

Methods: The clinical and immunological features of 36 patients with paraneoplastic neuropathy from the authors' database were analysed including the type and course of the neuropathy, associated tumours, and the presence of antineuronal and other autoantibodies.

Results: Antineuronal antibodies were detected in 17/36 patients (47%) and anti-Hu was the most frequent antineuronal antibody. Nine patients had high titre antinuclear antibodies (ANA, median titre 1/1000) without antineuronal antibodies. ANA reactivities were different in most patients. Comparison of the ANA positive and ANA negative patients revealed that ANA positive paraneoplastic neuropathy is more frequently associated with breast cancer but is not associated with lung cancer (p<0.05). The main clinical type in these patients was sensorimotor neuropathy. No ANA positive patient had central nervous system involvement. Although the Rankin score at the time of diagnosis was not different, the functional outcome in ANA positive patients was better than in ANA negative patients (p<0.05).

Conclusions: Paraneoplastic neuropathy is a heterogeneous disorder. ANA may define a subgroup of paraneoplastic neuropathy with different clinical and immunological features and may be related to better prognosis of the neuropathic symptoms.

Full Text

The Full Text of this article is available as a PDF (121.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoine J. C., Honnorat J., Camdessanché J. P., Magistris M., Absi L., Mosnier J. F., Petiot P., Kopp N., Michel D. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001 Feb;49(2):214–221. doi: 10.1002/1531-8249(20010201)49:2<214::aid-ana41>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  2. Antoine J. C., Mosnier J. F., Absi L., Convers P., Honnorat J., Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):7–14. doi: 10.1136/jnnp.67.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Azizah M. R., Azila M. N., Zulkifli M. N., Norita T. Y. The prevalence of antinuclear, anti-dsDNA, anti-Sm and anti-RNP antibodies in a group of healthy blood donors. Asian Pac J Allergy Immunol. 1996 Dec;14(2):125–128. [PubMed] [Google Scholar]
  4. Blaes F., Klotz M., Huwer H., Straub U., Kalweit G., Schimrigk K., Schäfers H. J. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg. 2000 Jan;69(1):254–258. doi: 10.1016/s0003-4975(99)01198-4. [DOI] [PubMed] [Google Scholar]
  5. Blaes F, Strittmatter M, Schwamborn J, Heide G, Hamann GF, Merkelbach S, Schimrigk K. Antineuronal antibody-associated paraneoplastic neuropathy in Hodgkin's disease. Eur J Neurol. 1998 Jan;5(1):109–112. doi: 10.1046/j.1468-1331.1998.510109.x. [DOI] [PubMed] [Google Scholar]
  6. Casiano C. A., Humbel R. L., Peebles C., Covini G., Tan E. M. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmun. 1995 Aug;8(4):575–586. doi: 10.1016/0896-8411(95)90009-8. [DOI] [PubMed] [Google Scholar]
  7. Chan K. H., Vernino S., Lennon V. A. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol. 2001 Sep;50(3):301–311. doi: 10.1002/ana.1127. [DOI] [PubMed] [Google Scholar]
  8. Covini G., Chan E. K., Nishioka M., Morshed S. A., Reed S. I., Tan E. M. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology. 1997 Jan;25(1):75–80. doi: 10.1002/hep.510250114. [DOI] [PubMed] [Google Scholar]
  9. Dalmau J., Furneaux H. M., Cordon-Cardo C., Posner J. B. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol. 1992 Oct;141(4):881–886. [PMC free article] [PubMed] [Google Scholar]
  10. Dalmau J., Graus F., Rosenblum M. K., Posner J. B. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992 Mar;71(2):59–72. doi: 10.1097/00005792-199203000-00001. [DOI] [PubMed] [Google Scholar]
  11. Fernández-Madrid F., VandeVord P. J., Yang X., Karvonen R. L., Simpson P. M., Kraut M. J., Granda J. L., Tomkiel J. E. Antinuclear antibodies as potential markers of lung cancer. Clin Cancer Res. 1999 Jun;5(6):1393–1400. [PMC free article] [PubMed] [Google Scholar]
  12. Fritzler M. J. Clinical relevance of autoantibodies in systemic rheumatic diseases. Mol Biol Rep. 1996;23(3-4):133–145. doi: 10.1007/BF00351161. [DOI] [PubMed] [Google Scholar]
  13. Graus F., Dalmou J., Reñ R., Tora M., Malats N., Verschuuren J. J., Cardenal F., Viñolas N., Garcia del Muro J., Vadell C. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997 Aug;15(8):2866–2872. doi: 10.1200/JCO.1997.15.8.2866. [DOI] [PubMed] [Google Scholar]
  14. Graus F., Delattre J. Y., Antoine J. C., Dalmau J., Giometto B., Grisold W., Honnorat J., Smitt P. Sillevis, Vedeler Ch, Verschuuren J. J. G. M. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135–1140. doi: 10.1136/jnnp.2003.034447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Graus F., Keime-Guibert F., Reñe R., Benyahia B., Ribalta T., Ascaso C., Escaramis G., Delattre J. Y. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001 Jun;124(Pt 6):1138–1148. doi: 10.1093/brain/124.6.1138. [DOI] [PubMed] [Google Scholar]
  16. Keime-Guibert F., Graus F., Broët P., Reñ R., Molinuevo J. L., Ascaso C., Delattre J. Y. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology. 1999 Nov 10;53(8):1719–1723. doi: 10.1212/wnl.53.8.1719. [DOI] [PubMed] [Google Scholar]
  17. Moll J. W., Hooijkaas H., van Goorbergh B. C., Roos L. G., Henzen-Logmans S. C., Vecht C. J. Systemic and anti-neuronal auto-antibodies in patients with paraneoplastic neurological disease. J Neurol. 1996 Jan;243(1):51–56. doi: 10.1007/BF00878531. [DOI] [PubMed] [Google Scholar]
  18. Morita S., Arima T., Matsuda M. Prevalence of nonthyroid specific autoantibodies in autoimmune thyroid diseases. J Clin Endocrinol Metab. 1995 Apr;80(4):1203–1206. doi: 10.1210/jcem.80.4.7714090. [DOI] [PubMed] [Google Scholar]
  19. Sillevis Smitt Peter, Grefkens Joost, de Leeuw Bertie, van den Bent Martin, van Putten Wim, Hooijkaas Herbert, Vecht Charles. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002 Jun;249(6):745–753. doi: 10.1007/s00415-002-0706-4. [DOI] [PubMed] [Google Scholar]
  20. Smitt P. S., Posner J. B. Paraneoplastic peripheral neuropathy. Baillieres Clin Neurol. 1995 Nov;4(3):443–468. [PubMed] [Google Scholar]
  21. Spadaro M., Amendolea M. A., Mazzucconi M. G., Fantozzi R., Di Lello R., Zangari P., Masala G. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler. 1999 Apr;5(2):121–125. doi: 10.1177/135245859900500209. [DOI] [PubMed] [Google Scholar]
  22. Yokokawa N., Aizawa T., Ishihara M., Koizumi Y., Yanagisawa K., Yamada T. Presence of anti-DNA antibody in diabetes mellitus: its relation to the duration of diabetes and diabetic complications. Metabolism. 1989 Sep;38(9):891–894. doi: 10.1016/0026-0495(89)90237-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES